1. Introduction {#s1}
===============

Children with inflammatory bowel disease \[IBD\] need to be monitored regularly in order to detect disease activity timely and to prevent complications, such as abscesses or stenoses. Gastrointestinal endoscopy and magnetic resonance enterography \[MRE\] are the gold standard diagnostic tests to detect disease activity and location, for large and small bowel resepectively.^[@CIT0001]^ However, both tests are invasive, expensive, and time-consuming, and it is therefore not feasible to perform them frequently in children. Hence, paediatricians frequently rely on non-invasive tools, such as clinical disease activity scales and biomarkers, such as C-reactive protein \[CRP\] and faecal calprotectin. However, these tools have limited accuracy^[@CIT0002],[@CIT0003]^ and do not provide information on disease location, whereas disease location is relevant---both in the diagnostic setting and during monitoring. As a consequence, paediatricians often still rely on endoscopy and MRE to be informed on disease activity and disease location. Therefore, IBD patients would benefit from the implementation of additional accurate non-invasive monitoring tools.

Ultrasound \[US\] is a promising example of such a tool. It is safe, fast, and cheap, and does not require any anaesthesia, and it can be used both for monitoring children with IBD and for children suspected of IBD.^[@CIT0004]^ US examinations provide information on, for instance, bowel wall thickness \[BWT\] and vascularity of the bowel wall, two important measures of inflammation.^[@CIT0005]^ In adult IBD patients, US has already shown its usefulness to assess disease activity. Meta-analyses showed pooled sensitivities and specificities ranging 84--90% and 92--97%, respectively.^[@CIT0006]^ However, due to the difference in habitus and disease behaviour between adults and children, these data cannot be directly extrapolated to the paediatric IBD population. It is known that US correlates well with clinical disease activity scales and biomarkers in paediatric IBD,^[@CIT0010]^ but as mentioned above, these monitoring tools have their pitfalls. Knowledge about the diagnostic accuracy compared with an adequate reference standard is therefore crucial, but literature addressing this topic is limited. If US could improve non-invasive monitoring by accurately detecting disease location and severity, health care and quality of life of IBD patients could be improved; targeted treatment could be started quicker, potentially preventing complications; and the need for colonoscopies and MREs could be reduced.^[@CIT0013]^

We performed a systematic review of currently published literature to answer the following question: 'What is the diagnostic accuracy of US in detecting IBD in suspected children and in detecting intestinal inflammation in paediatric IBD patients using MRE and/or ileo-colonoscopy as reference standard?' Secondary aims were to assess which items of the US examination were used for disease assessment, and to assess mean bowel wall thickness in paediatric IBD patients.

2. Methods {#s2}
==========

We conducted a search, with help of a clinical librarian \[FE\], in the PubMed, Embase \[Ovid\], Cochrane Library, and CINAHL \[EBSCO\] databases, looking for articles published from 1990 to July 2018. The search terms are available as Supplementary data at **ECCO-JCC** online. Inclusion criteria were: studies investigating the diagnostic accuracy of US in children \[aged 0--18 years\] with IBD or suspicion of IBD, using ileo-colonoscopy and/or MRE as the reference standard. Exclusion criteria were articles that did not report sensitivity/specificity or data to produce a 2 × 2 contingency table, and articles not published in English, Dutch, French, German, Spanish, or Italian. Furthermore, studies only using contrast enhanced ultrasonography \[CEUS\] or small intestine ultrasonography \[SICUS\] were excluded.

The titles and/or abstracts of the studies retrieved using the search strategy were screened independently by two reviewers \[EW and FV\] to identify studies that potentially met the inclusion criteria outlined above. The full texts of these potentially eligible studies were then retrieved and independently assessed for eligibility by the same two reviewers. Any disagreements were resolved through discussion with a third reviewer \[BK\].

A standardised, pre-piloted form was used to extract data and assess risk of bias of the included studies. The extracted information included: study setting; study population; participants' baseline characteristics; details of the ultrasound, MRE, and ileo-colonoscopy examinations; study design; recruitment and study completion rates; measures of accuracy; and patient satisfaction. We also noted the definition used for defining a US as positive, and references this choice was based on. In case a study did not report a specific definition, we noted the US items used \[i.e., BWT\]. Studies were subdivided into studies analysing accuracy at patient level \[i.e., whether there is any disease activity or not\] and studies analysing accuracy at segment level \[i.e., whether there is disease activity in a specific segment\]. Where needed, authors were contacted to retrieve additional information.

2.1. Risk of bias assessment {#s3}
----------------------------

The risk of bias was assessed using the QUADAS-2 tool.^[@CIT0014]^ This is a generic tool developed specifically for use in diagnostic test accuracy reviews. It contains four domains \[patient selection, index test, reference test, and flow and timing\] with different signalling questions to identify study characteristics that could result in bias. We modified the QUADAS-2 tool, adding two signalling questions recommended in the Cochrane Handbook for Systematic Reviews on Diagnostic Test Accuracy \[see [Table 3](#T3){ref-type="table"}\]^[@CIT0015]^: 'Did test operators have appropriate training?' and 'Was treatment withheld between performance of the index- and reference test?'. We defined an acceptable interval between US and reference standard as a maximum of 7 days, and we defined an appropriate training as having finished the radiology specialisation or another ultrasonography education.

2.2. Meta-analysis {#s4}
------------------

Criteria for inclusion in the meta-analysis were: 1\] interval between US and reference standard of 7 days or less; 2\] blinding of reference test \[i.e., endoscopy/MRE\] results during interpretation of US and blinding of US results during interpretation of reference standard; 3\] appropriate training of operators; and 4\] withholding of treatment in between US and reference standard examinations. For the meta-analysis, we planned to pool eligible studies in four separate groups: 1\] diagnostic studies comparing US with ileo-colonoscopy; 2\] diagnostic studies comparing US with MRE for small bowel disease; 3\] follow-up studies comparing US with ileo-colonoscopy; and 4\] follow-up studies comparing US with MRE for small bowel disease. In case a group contained two or more studies, we planned to calculate pooled sensitivity and specificity using Review Manager® version 5.0 and SAS \[SAS Institute, Cary, NC\] macro METADAS version 1.3, applying the bivariate method as recommended in the Cochrane Handbook for Systematic Reviews on Diagnostic Test Accuracy.^[@CIT0015]^

We also planned to perform a meta-analysis of all the studies describing bowel wall thickness \[BWT\] measurements assessed with US in different endoscopic disease activity categories \[i.e., remission, mild, moderate, and severe disease activity\]. The sample-size weighted pooled mean and pooled standard deviation \[SD\] scores per endoscopic disease activity category were calculated with Microsoft Excel® version 2016, and the differences between the categories were first assessed with analysis of variance \[ANOVA\] and subsequently with Student's t test for independent samples---corrected for multiple testing with Bonferroni---using GraphPad Prism® version 7; *p*-values of less than 0.017 were considered statistically significant \[= 0.05/3\].

3. Results {#s5}
==========

A total of 448 studies were found and, after exclusion of duplicates, 276 studies remained \[see [Figure 1](#F1){ref-type="fig"}\]. After title and abstract screening, 59 full texts were screened for eligibility. Reasons for exclusion were: different study population \[e.g., adult\] \[*n* = 33\]; different reference standard \[*n* = 4\]; different study design \[e.g., no accuracy study\] \[*n* = 4\]; and unavailability of full text \[*n* = 2\].

![PRISMA flow diagram. DTA, diagnostic test accuracy.](jjz085f0001){#F1}

Fourteen studies including a total of 424 patients were finally included in the review: 12 prospective and two retrospective studies. The number of included patients per study that underwent both US and reference standard examinations ranged from nine to 50. Eight studies compared US with endoscopy^[@CIT0016]^ and six studies US with MRE.^[@CIT0024]^ Characteristics of the included studies are depicted in [Table 1](#T1){ref-type="table"}, and the specifications of the US and MRE technique are available as Supplementary data at **ECCO-JCC** online. Two out of eight studies comparing US with endoscopy were performed in children with a clinical suspicion of IBD, four included both children with suspicion and those with known IBD, and two included only children with known IBD. From the studies comparing US with MRE, three included both children with suspicion and diagnosis of IBD, and the other three only included patients with known IBD. As depicted in [Table 1](#T1){ref-type="table"}, nine studies included both CD and UC patients, three studies included only CD patients, and one study included only UC patients.

###### 

Characteristics of included studies.

  First author *Country*                           n\* \[m/f\]    Mean age (range)   Aim (patient population)            Design   Cut-off value BWT                Items used for Disease Assessment                               Definition of positive US + reference                                          Time-interval US-reference     Segments evaluated                                               Analysis at segment or patient level \*\*\*\*
  ------------------------------------------------ -------------- ------------------ ----------------------------------- -------- -------------------------------- --------------------------------------------------------------- ------------------------------------------------------------------------------ ------------------------------ ---------------------------------------------------------------- -----------------------------------------------
  *Ileo-colonoscopy as reference test*                                                                                                                                                                                                                                                                                                                                                                            
  Alberini 2001 *France*^[@CIT0016]^               23 \[17/11\]   10 (2-15)          Diagnosis *(CD&UC)*\*\*             R        2 mm (colon), 2,5 mm (ileum)     BWT/ free fluid / lymph nodes                                   Increased BWT AND/OR (free fluid AND lymph nodes) ^[@CIT0023],[@CIT0037]^      Unspecified                    Colon, ileum                                                     Patient
  Bothe 2006 *Norway*^[@CIT0017]^                  15 \[23/20\]   12 (5-16)          Diagnosis *(CD&UC)*                 P        Unspecified                      BWT/ DS/ lymph nodes/ complications                             Unspecified                                                                    \<3 weeks                      Terminal ileum                                                   Segment
  de Ridder 2012\*\*\* *Netherlands*^[@CIT0020]^   19 \[14/6\]    15 (11-18)         Diagnosis *((suspicion) CD)*        P        3 mm                             BWT / SMA DS/ abscess                                           BWT AND/OR SMA DS (peak systole \> 100 cm/s in fasting children)^[@CIT0011]^   2-25 days (median 8)           Small bowel (duodenum, jejunum, ileum)                           Patient
  Ziech 2014 *Netherlands*^[@CIT0022]^             24 \[15/13\]   14 (10-17)         Diagnosis *(Suspicion CD & UC)*     P        3 mm                             BWT/ WLS / lymph nodes / DS                                     Unspecified                                                                    1-40 days (median 7.5)         Terminal ileum, colon                                            Patient
  Bremner 2006 *UK*^[@CIT0018]^                    33             12 (4-17)          Follow up *((suspicion) CD & UC)*   P        3 mm                             BWT + SMA DS                                                    Unspecified                                                                    \<10 days                      Colon                                                            Both
  Civitelli 2014 *Italy*^[@CIT0019]^               50 \[24/20\]   13 (3-18)          Follow up *(known UC)*              P        3 mm                             BWT, WLS, haustra visibility, DS                                2 of the following: BWT, WLS, haustra visibility, DS ^[@CIT0018],[@CIT0038]^   1 day                          Large bowel                                                      Both
  Faure 1997 *France*^[@CIT0023]^                  38             11 (4-18)          Follow up *((suspicion) CD & UC)*   P        2 mm (colon), 2,5 mm (ileum)     BWT & WLS                                                       Unspecified                                                                    1 day                          Terminal ileum, large bowel                                      Both
  Haber 2002 *Germany*^[@CIT0021]^                 41 \[43/35\]   11 (0-17)          Follow up *(Known CD & UC)*\*\*     P        1,5 mm (ileum), 2 mm (colon)     BWT & WLS                                                       BWT ^[@CIT0041]^                                                               Unspecified                    Terminal ileum, colon                                            Both
  *MRE as reference test*                                                                                                                                                                                                                                                                                                                                                                                         
  Ahmad 2016 *Canada*^[@CIT0024]^                  33             15 (7-18)          Follow up ((*suspicion) CD & UC)*   P        4 mm                             BWT/ DS/ stricture/ fistula/ creeping fat / lymph nodes.        Unspecified                                                                    2 hours                        Jejunum, ileum, terminal ileum, cecum, colon, sigmoid, rectum.   Both
  Barber 2017 *UK*^[@CIT0027]^                     49 \[33/16\]   4 (7-17)           Follow up *((suspicion) CD & UC)*   R        3 mm                             BWT/ abnormal echogenicity/ DS/ creeping fat                    Unspecified                                                                    IQR: 1--8 days                 Jejunum, ileum, terminal ileum, colon.                           Patient
  Tsai 2017 *USA*^[@CIT0028]^                      41 \[22/19\]   14 (5- 19)         Follow up *((suspicion) CD & UC)*   P        1.9 (rater1) / 1.8 (rater2) mm   BWT/ abnormal echogenicity/ DS/ creeping fat                    Unspecified                                                                    \<1 day                        Terminal ileum                                                   Segment
  Dagia 2008 *Australia*^[@CIT0029]^               9              Unspecified        Follow up (*Known CD)*              P        Unspecified                      BWT/ strictures/ mural abnormality/ creeping fat/ lymph nodes   Unspecified                                                                    0--54 weeks (median 7 weeks)   Unspecified                                                      Patient
  Dillman 2016 *USA*^[@CIT0026]^                   29 \[18/11\]   15 (9-18)          Follow up *(Known CD)*              P        Unspecified                      Unspecified                                                     Unspecified                                                                    1 hour                         Distal small bowel                                               Patient
  Magnano 2003 *Italy*^[@CIT0025]^                 20 \[10/12\]   15(8-18)           Follow up (*Known CD)*              P        Unspecified                      BWT + DS                                                        BWT + DS ^[@CIT0042]^                                                          \<7 days                       Unspecified                                                      Patient

BWT, bowel wall thickness; CD, Crohn's disease; DS, Doppler signal; P, prospective; R, retrospective; SMA, superior mesenteric artery; UC, ulcerative colitis; US, ultrasound; WLS, wall layer stratification; MRE, magnetic resonance enterography; IBD, inflammatory bowel disease; IQR, interquartile range.

\*Number of patients that underwent both US and reference standard, number of males/females in whole study.

\*\*Also included some non-IBD patients \[e.g., Behcet's disease, granulomatosis, and gastroenteritis\].

\*\*\* Used single-balloon enteroscopy as reference standard.

\*\*\*\*.See method section for explanation.

3.1. Definition used for assessing US {#s6}
-------------------------------------

Although 13 out of 14 studies did describe the US items they used for assessing the US examination, only four studies gave a clear description of their definition for an abnormal US result \[see [Table 2](#T2){ref-type="table"}\]. In all studies except for one, increased BWT was used as one of the criteria for an abnormal US result. Cut-off values for BWT ranged from 1.5 mm to 4 mm for all ages. Two out of 14 studies used different cut-off values for ileum and colon.^[@CIT0016],[@CIT0023]^ Other reported US items were: increased vascularity measured with Doppler \[*n* = 9\]; presence of enlarged lymph nodes \[*n*= 6\]; absence of wall layer stratification or presence of creeping fat \[*n* = 4\]; and abscesses or other complications \[*n* = 2\]. One study in UC patients also used absence of visible colonic haustrations as a criterion.

###### 

Risk of bias assessment using the QUADAS-2 tool.

  ----------------------
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3.2. Risk of bias assessment {#s7}
----------------------------

The details of the risk of bias assessment according to the QUADAS-2 tool are shown in [Table 3](#T3){ref-type="table"}. There was a wide spread in time interval between US and the reference test, from 1 h up to 54 weeks. In eight studies, the interval between US and reference standard was longer than 7 days or undefined. Most studies \[8/14\] did not describe whether US results were blinded during the interpretation of the reference standard, and in eight out of 14 studies it was not specified whether treatment was withheld in between US and reference test. Only two studies fulfilled the predefined criteria for inclusion in the meta-analyses.^[@CIT0024],[@CIT0026]^ However, the two studies included different types of patients \[suspicion of CD and UC versus known CD\], and different bowel segments were included in the analysis, and thus no meta-analysis could be performed.

###### 

Diagnostic accuracy of US compared with ileo-colonoscopy or MRE at patient level.

  Author                                 n    Aim (patient population)            Sensitivity (95% CI)\*\*   Specificity (95% CI)\*\*
  -------------------------------------- ---- ----------------------------------- -------------------------- --------------------------
  *Ileo-colonoscopy as reference test*                                                                       
  Alberini 2001                          23   Diagnosis *(CD&UC)*                 39% (20-61)\*              90% (68-99)\*
  de Ridder 2012                         19   Diagnosis *((suspicion) CD)*        54% (25-81)                100% (54-100)
  Ziech 2014                             24   Diagnosis *(suspicion CD & UC)*     55%                        100%
  Bremner 2006                           33   Follow up *((suspicion) CD & UC)*   48%                        93%
  Civitelli 2014                         50   Follow up *(known UC)*              100%                       93%
  Faure 1997                             38   Follow up *((suspicion) CD & UC)*   88%                        93%
  Haber 2002                             41   Follow up *(known CD & UC)*         77%                        83%
  *MRE as reference test*                                                                                    
  Ahmad 2016                             33   Follow up ((*suspicion) CD & UC)*   64%\* (45-80)\*            Not available
  Barber 2017                            49   Follow up *((suspicion) CD & UC)*   81% (70-89)                95% (92-97)
  Dagia 2008                             9    Follow up (*known CD)*              71%\* (29-96)\*            100%\* (16-100)\*
  Magnano 2003                           20   Follow up (*known CD)*              93%\* (68-100)\*           100%\* (48-100)\*

CD, Crohn's disease; UC, ulcerative colitis; MRE, magnetic resonance enterography; US, ultrasound; CI, confidence interval.

\*Calculated from raw data presented in article.

\*\*95% CI only calculated where possible

3.4. Accuracy of US in diagnosing IBD {#s8}
-------------------------------------

### 3.4.1. Endoscopy {#s9}

The results of the diagnostic accuracy at patient level are summarised in [Table 3](#T3){ref-type="table"}. Three studies assessed the accuracy of US in diagnosing IBD with ileo-colonoscopy as reference standard,^[@CIT0016],[@CIT0017],[@CIT0022]^ and one study used single-balloon enteroscopy as reference standard assessing the small bowel.^[@CIT0020]^ Point estimates of sensitivity of US in diagnosing endoscopically active IBD \[UC and CD combined\] ranged from 39% to 55% and specificity from 90% to 100%. One study assessed the accuracy of US for disease localisation in the terminal ileum at diagnosis of IBD; sensitivity was 93%. Sensitivity of US in diagnosing active small bowel CD was 54% and specificity 100% in the one study that used single-balloon enteroscopy.

### 3.4.2. MRE {#s10}

No study used MRE as reference standard to assess accuracy of US in diagnosing IBD.

3.5. Accuracy of US in follow-up of IBD {#s11}
---------------------------------------

### 3.5.1. Endoscopy {#s12}

Ten studies assessed the accuracy of US in detecting disease activity or assessing disease extent in IBD for purpose of follow-up. Four of those used ileo-colonoscopy as reference standard and performed analysis both at patient level and at segment level. In these four studies, sensitivity and specificity at patient level, including patients with both CU and CD, ranged from 48% to 93% and from 83% to 93%, respectively. The results for analysing each segment separately are depicted in [Table 4](#T4){ref-type="table"}. In nearly all segments, the specificity was found to be higher than the sensitivity, with a 4% to 46% difference.

###### 

Diagnostic accuracy of US compared with ileo-colonoscopy or MRE at segment level sorted on reference standard and study aim.

  Author                                 n    Aim *(patient population)*          Segment              Sensitivity (95% CI)\*\*   Specificity (95% CI)\*\*
  -------------------------------------- ---- ----------------------------------- -------------------- -------------------------- --------------------------
  *Ileo-colonoscopy as reference test*                                                                                            
  Borthne 2006                           15   Diagnosis *(CD&UC)*                 Term. ileum          93% (70--99)               \-
  Bremner 2006                           33   Follow up *((suspicion) CD & UC)*   Cecum                33%                        100%
                                                                                  Asc. colon           46%                        88%
                                                                                  Tran. colon          67%                        90%
                                                                                  Desc. colon          54%                        100%
                                                                                  Sigmoid              50%                        88%
  Civitelli 2014                         50   Follow up *(known UC)*              Asc. colon           75% (42-93)                100% (74-100)
                                                                                  Tran. colon          86% (60-97)                100% (70-100)
                                                                                  Desc. colon          96% (80-100)               100% (62-97)
  Faure 1997                             38   Follow up *((suspicion) CD & UC)*   Term. ileum          100%                       92%
                                                                                  Asc. colon           88%                        92%
                                                                                  Tran. colon          80%                        90%
                                                                                  Desc. colon          93%                        100%
                                                                                  Rectum               89%                        \-
  Haber 2002                             41   Follow up *(Known CD & UC)*         Ter. ileum           100%                       72%
                                                                                  Asc. colon           72%                        81%
                                                                                  Tran. colon          74%                        94%
                                                                                  Desc. colon          74%                        89%
  *MRE as reference test*                                                                                                         
  Dillman 2016                           29   Follow up *(Known CD)*              Distal small Bowel   83%\*                      71%\*
  Tsai 2017                              41   Follow up *((suspicion) CD & UC)*   Term. ileum          67% (rater1)               78% (rater1)
                                                                                                       83% (rater2)               78% (rater2)

Asc., ascending; CD, Crohn's disease; desc., descending; MRE, magnetic resonance enterography; ran., transverse; term., terminal; UC, ulcerative colitis; US, ultrasound.

\*Calculated from raw data presented in article.

\*\*95% CI only calculated where possible.

One study used a self-designed US activity index to detect colonic inflammation.^[@CIT0019]^ This study included only patients with UC and a suspected disease flare-up. The overall sensitivity and specificity for detection of severe disease were excellent \[100% and 93%, respectively\], the sensitivity in all different segments for detecting colonic lesions ranged from 75--96%, and the specificity was 100% in each part of the colon.

### 3.5.2. MRE {#s13}

A total of six studies used MRE as reference standard for assessing the accuracy of US in detecting disease activity or assessing disease extent in IBD for monitoring patients \[[Tables 3](#T3){ref-type="table"} and [4](#T4){ref-type="table"}\]. Four studies evaluated small bowel only, and in two studies the colon was also included in the analysis. As these two studies analysed their results at patient level, we could not report small bowel results only. Two out of six studies included patients with CD and patients with UC^[@CIT0024],[@CIT0027],[@CIT0028]^; the sensitivity at patient level ranged from 64% to 81%, and specificity was 95% in one study^[@CIT0027]^ but could not be calculated in the other study.^[@CIT0024]^ Two studies only included CD patients^[@CIT0025],[@CIT0029]^; sensitivity ranged from 71% to 93% and specificity was 100% in both studies. In two studies, the analysis was segment-based^[@CIT0026],[@CIT0028]^ \[see [Table 4](#T4){ref-type="table"}\].

3.6. Bowel wall thickness {#s14}
-------------------------

Three studies reported the differences in BWT between different categories of disease severity.^[@CIT0018],[@CIT0019],[@CIT0021]^ All studies described a statistically significant increase in BWT in moderately to severely inflamed segments. The sample-size weighted pooled means and pooled SD scores of the two studies that described BWT as measured by US in different categories of endoscopic disease activity in colon are displayed in [Figure 2](#F2){ref-type="fig"}^18,19^. Mean BWT \[and SD\] in patients in remission or with mild, moderate, or severe endoscopic disease activity, respectively, was 1.7 mm \[0.4\], 2.4 \[0.4\] mm, 3.5 \[0.5\] mm, and 4.8 \[0.7\] mm. The other study used clinical disease activity as reference standard and was thus not included in this figure.

![Mean (+standard deviation \[SD\]) colonic bowel wall thickness \[BWT\] as assessed with US in different categories of endoscopic disease activity. Differences are tested with analysis of variance \[ANOVA\] and subsequently Student's t test, corrected for multiple testing with Bonferroni.](jjz085f0002){#F2}

4. Discussion {#s15}
=============

This systematic review shows that the diagnostic accuracy of US in detecting intestinal inflammation as seen on MRE and/or ileo-colonoscopy in paediatric IBD patients remains inconclusive. Most studies had important methodological limitations, such as an inefficient time flow and unclear blinding procedures, and the reported accuracy varied widely between studies. In addition, we establish that there is no generally accepted or applied definition of an abnormal US result.

The role of US in detection of inflammation in the adult population has been studied extensively.^[@CIT0005]^ In a meta-analysis of Fraquelli *et al*. studying the role of US in the detection of CD and including seven studies, a pooled sensitivity and specificity of 88% and 93% \[95% CI not reported\] were found.^[@CIT0007]^ Similar results were found in a subsequent systematic review of Dong *et al.* (sensitivity 88% \[95% CI: 85--91%\], specificity 97% \[95% CI: 96--98%\]) which included 15 studies and described the diagnostic accuracy of US in the diagnosis of CD and the evaluation of disease activity.^[@CIT0009]^ As in the adult studies, our results show higher specificity rates compared with sensitivity. This may be explained by the fact that superficial endoscopic lesions do not always cause intramural changes such as an increased bowel wall thickness, as was also pointed out by Magnano *et al*.^[@CIT0025]^

However, we are unable to reliably interpret the diagnostic accuracy results reported in this systematic review because of the major methodological shortcomings of the included studies. Most of the studies included in this review did not meet the predefined criteria for inclusion in the meta-analysis, which raises questions about the validity of the presented results. The limited quality can be partly explained by the fact that we included two retrospective studies and two studies that were not designed to study diagnostic accuracy of US, but from which raw data could be derived. The primary aim of these studies was to assess the accuracy of MRE or scintigraphy.^[@CIT0016],[@CIT0025]^ The most common reasons for exclusion from the meta-analysis were an unacceptable time interval between the US and the reference standard, and lack of data on whether treatment was withheld during this interval. However, these two are very important, since BWT can already change significantly after 2 weeks of treatment.^[@CIT0030]^

In addition, an important finding in this systematic review is that only few studies defined what was considered an abnormal US result, although most did describe the US features they took into account, such as BWT or increased vascularity. Only abnormal BWT was often defined; however, there was a wide spread in cut-off values for BWT, ranging from 1.5 to 4 mm. According to several studies assessing the bowel wall in healthy children using US, the mean colonic wall thickness is 1.2 mm and does not reach 2 mm.^[@CIT0031]^ As we show \[[Figure 2](#F2){ref-type="fig"}\], the mean colonic wall thickness in paediatric IBD patients in remission is 1.6 mm \[SD 0.4\] and is 2.4 mm \[SD 0.4\] in patients with mild inflammation. This suggests that for this US feature, the optimal cut-off may be 2--3 mm. However, this presumption remains to be confirmed in future prospective studies. It is necessary to formulate standard criteria for an abnormal US result, and preferably also to develop a validated activity index, combining several US items in a score.^[@CIT0034]^ To date, only Civitelli *et al*. aimed to design such an index for children with UC, showing promising results.^[@CIT0019]^ However, this index has not been externally validated.

A limitation in this systematic review was that we could not distinguish between CD and UC in most studies, although both illnesses are characterised by different features.^[@CIT0035]^ Additionally we aimed to assess MRE solely as reference standard for small bowel, as endoscopy is still the gold standard for large bowel assessment.^[@CIT0001]^ However, this was not possible in every study, as some studies using MRE only reported analysis at patient level and not at segment level.^[@CIT0025],[@CIT0027],[@CIT0029]^ Another discussion point is our definition used for 'appropriate training of test operators', which we defined as having finished the radiology specialisation or another ultrasonography education. Training is relevant, because an important and frequently reported downside of US is its operator dependency.^[@CIT0036]^ The results of Barber *et al*. suggest the presence of a learning curve when assessing an intestinal US, as the accuracy of the first 10 examinations was lower in comparison with the last 10 examinations.^[@CIT0027]^ Although we cannot determine whether our definition used is strict enough, we do not think it biased the results presented in this systematic review, as we did not pool our data. It would be valuable to define quality criteria for performing intestinal US, both in the research setting and in clinical practice.

To our knowledge, this is the first systematic review summarising the literature on the diagnostic accuracy of US to assess intestinal inflammation in paediatric IBD. The strengths of this review are: that we solely included studies using a proper reference standard; the use of a validated tool for risk of bias assessment^14;^ and the strict criteria for inclusion in the meta-analyses, to avoid pooling biased data. Although US seems a promising non-invasive diagnostic tool for children with IBD, this review shows that the accuracy of US in detecting intestinal inflammation in this group of patients has not been accurately established yet. More evidence is needed to accurately determine the diagnostic value of US in IBD. Future studies: should be specific on the definition of an abnormal US result; should explore the use of indices combining several US features; should guarantee an efficient time flow between US and reference test; and should be strict in blinding procedures in order to prevent bias. Additionally, studies should include sufficient participants to reach a proper power.

4.1. Conclusion {#s16}
---------------

The diagnostic accuracy of US in children with IBD has not been established. High-quality prospective studies of adequate sample size are needed before US can be reliably used for the purposes of paediatric IBD diagnosis and monitoring disease activity.
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